代谢相关脂肪性肝病与结直肠肿瘤相关性的研究进展
Research Progress of the Relationship between Metabolic-Associated Fatty Liver Disease and Colorectal Neoplasia
摘要: 代谢相关脂肪性肝病(metabolic-associated fatty liver disease, MAFLD)原名非酒精性脂肪肝(non-alcoholic fatty liver disease, NAFLD),被认为是代谢综合征的肝脏表现,已成为发达国家和发展中国家最常见的慢性肝病,预计患病率在未来几年仍会有所上升,是终末期肝脏疾病、肝癌和肝移植的主要原因,影响着全球人口的1/3。结直肠癌(colorectal cancer, CRC)通过腺瘤–癌序列发展,是全球发病率第三、死亡率第二的恶性肿瘤。研究表明,MAFLD与总体癌症发病率增加相关,肿瘤是MAFLD患者第二大常见死因。既往已有多项研究发现NAFLD与结直肠肿瘤(colorectal neoplasia, CRN)存在相关性,但鉴于MAFLD与NAFLD诊断标准存在差异,MAFLD与CRN的相关性应得到进一步探索,本文旨在对MAFLD与CRN相关性进行综述,进而为CRN的预防与治疗提供新思路。
Abstract: Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is considered as the liver manifestation of metabolic syndrome. It has become the most common chronic liver disease in both developed and developing countries, with prevalence expected to increase in the coming years, and is the leading cause of end-stage liver disease, liver cancer, and liver transplantation, affecting one-third of the global population. Colorectal cancer (CRC) develops through the adenomato-cancer sequence, and is the third most common malignant tumor in the world with the second highest mortality rate. Studies have shown that MAFLD is associated with an increased incidence of cancer overall, and tumors are the second most common cause of death in people with MAFLD. Many studies have found a correlation between NAFLD and colorectal neoplasia (CRN). However, due to differences in diagnostic criteria between MAFLD and NAFLD, the correlation between MAFLD and CRN should be further explored. This article aims to review the correlation between MAFLD and CRN, so as to provide new ideas for the prevention and treatment of CRN.
文章引用:包杨, 晁冠群. 代谢相关脂肪性肝病与结直肠肿瘤相关性的研究进展[J]. 临床医学进展, 2025, 15(2): 1996-2004. https://doi.org/10.12677/acm.2025.152562

参考文献

[1] Beygi, M., Ahi, S., Zolghadri, S. and Stanek, A. (2024) Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions. Nutrients, 16, Article 2220. [Google Scholar] [CrossRef] [PubMed]
[2] European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. (2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 64, 1388-1402.
[3] Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
[4] Eslam, M., Sanyal, A.J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., et al. (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 158, 1999-2014.e1. [Google Scholar] [CrossRef] [PubMed]
[5] Eslam, M., Sarin, S.K., Wong, V.W., Fan, J., Kawaguchi, T., Ahn, S.H., et al. (2020) The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease. Hepatology International, 14, 889-919. [Google Scholar] [CrossRef] [PubMed]
[6] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[7] Chan, K.E., Koh, T.J.L., Tang, A.S.P., Quek, J., Yong, J.N., Tay, P., et al. (2022) Global Prevalence and Clinical Characteristics of Metabolic-Associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism, 107, 2691-2700. [Google Scholar] [CrossRef] [PubMed]
[8] Subramanian, P., Hampe, J., Tacke, F. and Chavakis, T. (2022) Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). International Journal of Molecular Sciences, 23, Article 6996. [Google Scholar] [CrossRef] [PubMed]
[9] Kang, S.H., Cho, Y., Jeong, S.W., Kim, S.U. and Lee, J. (2021) From Nonalcoholic Fatty Liver Disease to Metabolic-Associated Fatty Liver Disease: Big Wave or Ripple? Clinical and Molecular Hepatology, 27, 257-269. [Google Scholar] [CrossRef] [PubMed]
[10] Lin, S., Huang, J., Wang, M., Kumar, R., Liu, Y., Liu, S., et al. (2020) Comparison of MAFLD and NAFLD Diagnostic Criteria in Real World. Liver International, 40, 2082-2089. [Google Scholar] [CrossRef] [PubMed]
[11] Kim, K., Hong, S., Ahn, H. and Park, C. (2023) Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study. Diabetes & Metabolism Journal, 47, 220-231. [Google Scholar] [CrossRef] [PubMed]
[12] Zhao, J., Liu, L., Cao, Y., Gao, X., Targher, G., Byrne, C.D., et al. (2024) MAFLD as Part of Systemic Metabolic Dysregulation. Hepatology International, 18, 834-847. [Google Scholar] [CrossRef] [PubMed]
[13] Zhou, X., Cai, J., Targher, G., Byrne, C.D., Shapiro, M.D., Sung, K., et al. (2022) Metabolic Dysfunction-Associated Fatty Liver Disease and Implications for Cardiovascular Risk and Disease Prevention. Cardiovascular Diabetology, 21, Article No. 270. [Google Scholar] [CrossRef] [PubMed]
[14] Kaya, E. and Yilmaz, Y. (2021) Metabolic-Associated Fatty Liver Disease (MAFLD): A Multi-Systemic Disease beyond the Liver. Journal of Clinical and Translational Hepatology, 10, 329-338. [Google Scholar] [CrossRef] [PubMed]
[15] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[16] Hill, M.J., Morson, B.C. and Bussey, H.J.R. (1978) ÆTIOLOGY of Adenoma—Carcinoma Sequence in Large Bowel. The Lancet, 311, 245-247. [Google Scholar] [CrossRef] [PubMed]
[17] Stadlmayr, A., Aigner, E., Steger, B., Scharinger, L., Lederer, D., Mayr, A., et al. (2011) Nonalcoholic Fatty Liver Disease: An Independent Risk Factor for Colorectal Neoplasia. Journal of Internal Medicine, 270, 41-49. [Google Scholar] [CrossRef] [PubMed]
[18] Cho, Y., Lim, S., Joo, S.K., Jeong, D., Kim, J.H., Bae, J.M., et al. (2019) Nonalcoholic Steatohepatitis Is Associated with a Higher Risk of Advanced Colorectal Neoplasm. Liver International, 39, 1722-1731. [Google Scholar] [CrossRef] [PubMed]
[19] Chang, J., Chang, Y., Cho, Y., Jung, H., Park, D., Park, S., et al. (2023) Metabolic-Associated Fatty Liver Disease Is Associated with Colorectal Adenomas in Young and Older Korean Adults. Liver International, 43, 2548-2559. [Google Scholar] [CrossRef] [PubMed]
[20] Chung, G.E., Yu, S.J., Yoo, J., Cho, Y., Lee, K., Shin, D.W., et al. (2023) Differential Risk of 23 Site-Specific Incident Cancers and Cancer-Related Mortality among Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Population-Based Cohort Study with 9.7 Million Korean Subjects. Cancer Communications, 43, 863-876. [Google Scholar] [CrossRef] [PubMed]
[21] Fukunaga, S., Nakano, D., Kawaguchi, T., Eslam, M., Ouchi, A., Nagata, T., et al. (2021) Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. International Journal of Molecular Sciences, 22, Article 5462. [Google Scholar] [CrossRef] [PubMed]
[22] Gong, Y., Kang, J., Wang, X., Zheng, Y., Sui, Y. and Lu, W. (2023) Increased Detection Rates of Advanced Colorectal Adenoma in Women with Metabolic Dysfunction-Associated Fatty Liver Disease. Heliyon, 9, e22391. [Google Scholar] [CrossRef] [PubMed]
[23] Lee, H., Lee, H.W., Kim, S.U. and Chang Kim, H. (2022) Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. Clinical and Translational Gastroenterology, 13, e00435. [Google Scholar] [CrossRef] [PubMed]
[24] Seo, J., Bae, J., Kwak, M., Yang, J., Chung, S., Yim, J., et al. (2021) The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. Biomedicines, 9, Article 1401. [Google Scholar] [CrossRef] [PubMed]
[25] Xiong, J., Wu, Y., Chen, D., Zhang, Z., Liu, Y., Luo, J., et al. (2024) MAFLD with Central Obesity Is Associated with Increased Risk of Colorectal Adenoma and High-Risk Adenoma. BMC Gastroenterology, 24, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[26] Zeng, Y., Cao, R., Tao, Z. and Gao, Y. (2022) Association between the Severity of Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Colorectal Neoplasm: A Systematic Review and Meta-Analysis. Lipids in Health and Disease, 21, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[27] Zhai, D., Xu, S., Liu, H. and Tong, X. (2024) Nonalcoholic or Metabolic-Associated Fatty Liver Disease and Colorectal Polyps: Evidence from Meta-Analysis and Two-Sample Mendelian Randomization. Frontiers in Genetics, 15, Article 1422827. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, Z., Lin, C., Suo, C., Zhao, R., Jin, L., Zhang, T., et al. (2022) Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of 24 Specific Cancers. Metabolism, 127, Article 154955. [Google Scholar] [CrossRef] [PubMed]
[29] Wong, V.W.-., Wong, G.L, Tsang, S.W., Fan, T., Chu, W.C., Woo, J., et al. (2011) High Prevalence of Colorectal Neoplasm in Patients with Non-Alcoholic Steatohepatitis. Gut, 60, 829-836. [Google Scholar] [CrossRef] [PubMed]
[30] Ze, E.Y., Kim, B.J., Jun, D.H., Kim, J.G., Kang, H. and Lee, D.Y. (2018) The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. Diseases of the Colon & Rectum, 61, 36-42. [Google Scholar] [CrossRef] [PubMed]
[31] Ahn, J.S., Sinn, D.H., Min, Y.W., Hong, S.N., Kim, H.S., et al. (2016) Non-Alcoholic Fatty Liver Diseases and Risk of Colorectal Neoplasia. Alimentary Pharmacology & Therapeutics, 45, 345-353. [Google Scholar] [CrossRef] [PubMed]
[32] Kim, M.C., Park, J.G., Jang, B.I., Lee, H.J. and Lee, W.K. (2019) Liver Fibrosis Is Associated with Risk for Colorectal Adenoma in Patients with Nonalcoholic Fatty Liver Disease. Medicine, 98, e14139. [Google Scholar] [CrossRef] [PubMed]
[33] Wu, Y., Kumar, R., Wang, M., Singh, M., Huang, J., Zhu, Y., et al. (2021) Validation of Conventional Non-Invasive Fibrosis Scoring Systems in Patients with Metabolic Associated Fatty Liver Disease. World Journal of Gastroenterology, 27, 5753-5763. [Google Scholar] [CrossRef] [PubMed]
[34] Park, H., Yoon, E.L., Kim, M., Lee, J., Kim, J., Cho, S., et al. (2021) Comparison of Diagnostic Performance between FIB-4 and NFS in Metabolic-Associated Fatty Liver Disease Era. Hepatology Research, 52, 247-254. [Google Scholar] [CrossRef] [PubMed]
[35] Theofilis, P., Vordoni, A. and Kalaitzidis, R.G. (2022) Metabolic Dysfunction-Associated Fatty Liver Disease in the National Health and Nutrition Examination Survey 2017-2020: Epidemiology, Clinical Correlates, and the Role of Diagnostic Scores. Metabolites, 12, Article 1070. [Google Scholar] [CrossRef] [PubMed]
[36] Han, A.L. (2022) Validation of Fatty Liver Index as a Marker for Metabolic Dysfunction-Associated Fatty Liver Disease. Diabetology & Metabolic Syndrome, 14, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[37] Cheung, J.T.K., Zhang, X., Wong, G.L., Yip, T.C., Lin, H., Li, G., et al. (2023) MAFLD Fibrosis Score: Using Routine Measures to Identify Advanced Fibrosis in Metabolic-Associated Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 58, 1194-1204. [Google Scholar] [CrossRef] [PubMed]
[38] 张莉敏, 孙军. FIB-4在代谢相关脂肪性肝病合并结直肠腺瘤性息肉患者的预测价值[J]. 临床荟萃, 2022, 37(4): 334-338.
[39] Khan, R.S., Bril, F., Cusi, K. and Newsome, P.N. (2019) Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology, 70, 711-724. [Google Scholar] [CrossRef] [PubMed]
[40] Lim, S., Kim, J. and Targher, G. (2021) Links between Metabolic Syndro me and Metabolic Dysfunction-Associated Fatty Liver Disease. Trends in Endocrinology & Metabolism, 32, 500-514. [Google Scholar] [CrossRef] [PubMed]
[41] Yoon, Y.S., Keum, N., Zhang, X., Cho, E. and Giovannucci, E.L. (2015) Hyperinsulinemia, Insulin Resistance and Colorectal Adenomas: A Meta-Analysis. Metabolism, 64, 1324-1333. [Google Scholar] [CrossRef] [PubMed]
[42] Giovannucci, E. (2007) Metabolic Syndrome, Hyperinsulinemia, and Colon Cancer: A Review. The American Journal of Clinical Nutrition, 86, 836S-842S. [Google Scholar] [CrossRef] [PubMed]
[43] Kasprzak, A. (2021) Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. International Journal of Molecular Sciences, 22, Article 6434. [Google Scholar] [CrossRef] [PubMed]
[44] Jin, T. (2008) Why Diabetes Patients Are More Prone to the Development of Colon Cancer? Medical Hypotheses, 71, 241-244. [Google Scholar] [CrossRef] [PubMed]
[45] Barb, D., Williams, C.J., Neuwirth, A.K. and Mantzoros, C.S. (2007) Adiponectin in Relation to Malignancies: A Review of Existing Basic Research and Clinical Evidence. The American Journal of Clinical Nutrition, 86, 858S-866S. [Google Scholar] [CrossRef] [PubMed]
[46] Barbalho, S.M., Méndez-Sánchez, N. and Fornari Laurindo, L. (2023) Adiporon and ADP355, Adiponectin Receptor Agonists, in Metabolic-Associated Fatty Liver Disease (MAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Biochemical Pharmacology, 218, Article 115871. [Google Scholar] [CrossRef] [PubMed]
[47] Fenton, J.I., Birmingham, J.M., Hursting, S.D. and Hord, N.G. (2008) Adiponectin Blocks Multiple Signaling Cascades Associated with Leptin-Induced Cell Proliferation in Apcmin/+ Colon Epithelial Cells. International Journal of Cancer, 122, 2437-2445. [Google Scholar] [CrossRef] [PubMed]
[48] Kobashi, C., Urakaze, M., Kishida, M., Kibayashi, E., Kobayashi, H., Kihara, S., et al. (2005) Adiponectin Inhibits Endothelial Synthesis of Interleukin-8. Circulation Research, 97, 1245-1252. [Google Scholar] [CrossRef] [PubMed]
[49] Yoneda, K., Tomimoto, A., Endo, H., et al. (2008) Expression of Adiponectin Receptors, AdipoR1 and AdipoR2, in Normal Colon Epithelium and Colon Cancer Tissue. Oncology Reports, 20, 479-483.
[50] Valenzuela-Vallejo, L., Chrysafi, P., Kouvari, M., Guatibonza-Garcia, V., Mylonakis, S.C., Katsarou, A., et al. (2023) Circulating Hormones in Biopsy-Proven Steatotic Liver Disease and Steatohepatitis: A Multicenter Observational Study. Metabolism, 148, Article 155694. [Google Scholar] [CrossRef] [PubMed]
[51] Yamaji, T., Iwasaki, M., Sasazuki, S. and Tsugane, S. (2010) Interaction between Adiponectin and Leptin Influences the Risk of Colorectal Adenoma. Cancer Research, 70, 5430-5437. [Google Scholar] [CrossRef] [PubMed]
[52] Ji, J., Sun, J., Li, J., Xie, J., Xi, B. and Zhao, M. (2024) Altered Gut Microbiome Associated with Metabolic-Associated Fatty Liver Disease in Chinese Children. Clinical Nutrition, 43, 187-196. [Google Scholar] [CrossRef] [PubMed]
[53] Yang, Q., Zhang, L., Li, Q., Gu, M., Qu, Q., Yang, X., et al. (2022) Characterization of Microbiome and Metabolite Analyses in Patients with Metabolic Associated Fatty Liver Disease and Type II Diabetes Mellitus. BMC Microbiology, 22, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[54] Yang, C., Xu, J., Xu, X., Xu, W., Tong, B., Wang, S., et al. (2023) Characteristics of Gut Microbiota in Patients with Metabolic Associated Fatty Liver Disease. Scientific Reports, 13, Article No. 9988. [Google Scholar] [CrossRef] [PubMed]
[55] Oh, J.H., Lee, J.H., Cho, M.S., Kim, H., Chun, J., Lee, J.H., et al. (2021) Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients, 13, Article 1013. [Google Scholar] [CrossRef] [PubMed]
[56] Adolph, T.E., Grander, C., Moschen, A.R. and Tilg, H. (2018) Liver-Microbiome Axis in Health and Disease. Trends in Immunology, 39, 712-723. [Google Scholar] [CrossRef] [PubMed]
[57] Alisi, A., McCaughan, G. and Grønbæk, H. (2024) Role of Gut Microbiota and Immune Cells in Metabolic-Associated Fatty Liver Disease: Clinical Impact. Hepatology International, 18, 861-872. [Google Scholar] [CrossRef] [PubMed]
[58] Wong, C.C. and Yu, J. (2023) Gut Microbiota in Colorectal Cancer Development and Therapy. Nature Reviews Clinical Oncology, 20, 429-452. [Google Scholar] [CrossRef] [PubMed]
[59] Liu, Q., Han, M., Li, M., Huang, X., Feng, R., Li, W., et al. (2023) Shift in Prevalence and Systemic Inflammation Levels from NAFLD to MAFLD: A Population-Based Cross-Sectional Study. Lipids in Health and Disease, 22, Article No. 185. [Google Scholar] [CrossRef] [PubMed]
[60] Schmitt, M. and Greten, F.R. (2021) The Inflammatory Pathogenesis of Colorectal Cancer. Nature Reviews Immunology, 21, 653-667. [Google Scholar] [CrossRef] [PubMed]
[61] Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. (2006) The Fatty Liver Index: A Simple and Accurate Predictor of Hepatic Steatosis in the General Population. BMC Gastroenterology, 6, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[62] Shah, A.G., Lydecker, A., Murray, K., Tetri, B.N., Contos, M.J. and Sanyal, A.J. (2009) Comparison of Noninvasive Markers of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 7, 1104-1112. [Google Scholar] [CrossRef] [PubMed]
[63] Wai, C., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S., et al. (2003) A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C. Hepatology, 38, 518-526. [Google Scholar] [CrossRef] [PubMed]
[64] Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. (2007) The NAFLD Fibrosis Score. Hepatology, 45, 846-854. [Google Scholar] [CrossRef] [PubMed]
[65] Harrison, S.A., Oliver, D., Arnold, H.L., Gogia, S. and Neuschwander-Tetri, B.A. (2008) Development and Validation of a Simple NAFLD Clinical Scoring System for Identifying Patients without Advanced Disease. Gut, 57, 1441-1447. [Google Scholar] [CrossRef] [PubMed]